Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
NVDA -0.4EWJ 0.37TECK.B.TO -2.09CNQ.TO 0.71HHL.TO 0.075SYLD 0.03HAC.TO 0.04TRU -0.01
Daily Stock Opinions and Ratings
Stockchase Opinions

Lorne SteinbergViatrisVTRSBUYAug 04, 2023

Share price flat, but owns shares.
Excellent business within healthcare sector.
Getting into new business lines.
4% dividend yield with lots of free cash flow.
Share buybacks good for shareholders.
Trading at 4x earnings.

Lorne SteinbergLorne Steinberg
Owned
Unlock Rating
$10.60

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Viatris(VTRS)

Dec 21, 2023
Stockchase Research Editor: Michael O'Reilly

The pharma company produces Lipitor as one of its brands.  It has embarked on a divestiture strategy that is allowing it to focus on core competencies and reduce costs.  The are on target for $450 million in new product launches.  It trades at 7x earnings and below book value.  Cash reserves are growing as debt is aggressively retired.  Its dividend is backed by a payout ratio under one-third of cash flow.  We recommend placing a stop-loss at $8.50, looking to achieve $41 -- upside potential of 30%.  Yield 4.5%      

(Analysts’ price target is $14.11)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$10.55

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
RISKY

Viatris(VTRS)

Apr 14, 2023

Product of recent merger of two separate pharma business'.
New CEO - remains to be seen whether he will preform.
Would like to see stabilization on business before investing.
Too early to invest. 

Photo of Michael Hakes - CFA, MBAMichael Hakes - CFA, MBA
No
Unlock Rating
$9.85

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
TOP PICK

Viatris(VTRS)

Mar 13, 2023

It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its investment grade bond issues are in rock solid shape. It sold a division for $2 billion and will use the cash for a couple of acquisitions in eye wear and to buy back stock. There are potential sales of other smaller divisions so there could be more buybacks plus paying down debt. The dividend yield is 4.1%. Has a low price due to a couple of disappointing quarters but numbers have been solid since. Also revenues have been flat-lining.
Buy 4   Hold 10   Sell 0

(Analysts’ price target is $13.09)
Photo of Lorne SteinbergLorne Steinberg
Owned
Unlock Rating
$9.87

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Viatris(VTRS)

Mar 01, 2023

Global healthcare, mix of branded drugs and generics. Drug business has had a good run, but there's going to be significant pushback on the outsized profits, both globally and in the US. He prefers medical devices.

Photo of Brendan CaldwellBrendan Caldwell
No
Unlock Rating
$11.32

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
PAST TOP PICK

Viatris(VTRS)

Jan 23, 2023
(A Top Pick Jan 27/22, Down 17%) It sold a division for $2 billion with a chunk of that money going to the purchase of a couple of eye-care companies. It is trading at 4X earnings and buying back lots of stock. It covers a number of areas including oncology, the central nervous system, anesthetics and will narrow this down to areas such as diabetes and cardio vascular which have good growth ahead of them.
Photo of Lorne SteinbergLorne Steinberg
Owned
Unlock Rating
$11.82

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
BUY

Viatris(VTRS)

Nov 01, 2022
Pharmaceutical company that sells generic drugs. Healthy dividend yield and cash flow. About to close on M&A deal. Big question is whether company will return capital to shareholders (share buybacks). Shares very cheap at current price.
Photo of Lorne SteinbergLorne Steinberg
Owned
Unlock Rating
$10.24

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
HOLD

Viatris(VTRS)

Aug 25, 2022
Trading at 4x earnings. Disappointed Wall Street. Finally stabilized earnings. Asset sale later this year will bring in a fair bit of money. He anticipates a share buyback, decent cashflow, decent dividend to continue. Strategy becoming more apparent.
Photo of Lorne SteinbergLorne Steinberg
Owned
Unlock Rating
$10.16

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
BUY

Viatris(VTRS)

Jul 26, 2022
Later this year they will complete the sale of a business and the company could (probably) buy back 10% of shares with that cash. Be patient. Trades at only 3-4x earnings. So a buyback will be a big boost to shares. Early on their reports disappointed but lately has been alright. This flies under the radar.
Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$9.90

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
BUY

Viatris(VTRS)

Jun 21, 2022
It's the cheapest stock he owns, trading at 3x earnings. They generate fresh cash flow. They close the sale in late 2022 of one of their divisions. He expects them to use a major share buyback with those proceeds, and a bump in the share price finally. This is an incredible value stock or everybody is missing something. We'll see.
Photo of Lorne SteinbergLorne Steinberg
Owned
Unlock Rating
$10.60

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Viatris(VTRS)

May 12, 2022
Once they spun out their biosimilar business, he sold. Saw lots of debt, drugs coming off patent and pricing pressure, not a lot of growth. Value trap, even at these levels.
Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$10.75

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
HOLD

Viatris(VTRS)

May 11, 2022
Underperformer. Profitable, free cashflow positive. Out of favour. Profits from sale of biosimilar business will be used to buy back shares, which he approves of. Compellingly cheap at 3x earnings. Paying down debt.
Photo of Lorne SteinbergLorne Steinberg
Owned
Unlock Rating
$10.46

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
HOLD

Viatris(VTRS)

Apr 06, 2022
Cheapest stock in his portfolio, at a PE of 4. Free cashflow and dividend payer. Market didn't like lukewarm guidance. Either he's missing something, or it won't take much for the stock to outperform.
Photo of Lorne SteinbergLorne Steinberg
Owned
Unlock Rating
$10.65

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Viatris(VTRS)

Feb 03, 2022
Includes boring drugs, which provide consistent cashflows. Bit of growth in its biosimilar business, but talk of selling that. Range bound, limited growth, fair amount of debt, but tolerable for the type of assets. Low margin generics are more sensitive to inflationary risks. Dividend is probably safe.
Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$15.13

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare
TOP PICK

Viatris(VTRS)

Jan 27, 2022
Huge free cashflow. PE ratio is 4, not 14, but 4. Stock disappointed investors last year, Q3 was above expectations, expects Q4 to be strong. Needs very little to go right for them to do well. Went up in the recent down market. How can you not buy it? Yield is 3.25%. (Analysts’ price target is $18.62)
Photo of Lorne SteinbergLorne Steinberg
Owned
Unlock Rating
$14.78

Stock price when the opinion was issued

$15.37

As of Jun 18, 2026. Market Open.

Pharma & Healthcare

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

VEEV 0$153.3
WSP.TO 1.13$176.7
VRTX 0.47$452.1
OTEX.TO 0.24$29.47
CCO.TO 0.61$151.07
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

NVDA -0.4$210.29
EWJ 0.37$96.63
TECK.B.T… -2.09$88.93
CNQ.TO 0.71$58.66
HHL.TO 0.075$6.865

Popular Articles

Latest Sell Signals

TD.TO 0.7$169.33
MBLY -0.03$8.43
ASAN 0.03$6.95
MODG -0.01$18.21
NVTS 0$24.02

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Brian Acker, CA

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video